Treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urinary urgency and urinary frequency.
Special Populations
Prolonged half-life in geriatric patients, patients with moderate hepatic impairment (Child-Pugh class B), and patients with severe renal impairment (Clcr <30 mL/minute).
How it works
Overactive bladder is a urological condition related to problem with urination. The hallmark symptom of overactive bladder is urgency, but the diagnosis also includes frequent urination, frequent interruptions of sleep because of the need to urinate (nocturia), and urinating unintentionally followed by an urge to continue (urge incontinence).
Solifenacin is a medicine of the antimuscarinic class and was developed for treating contraction of overactive bladder with urge incontinence
How it works:
Solifenacin is a competitive cholinergic receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine and reducing the number of micturition, urgency and incontinence episodes. Because of a long elimination half life, a once-a-day dose can offer 24-hour control of the urinary bladder smooth muscle tone.
Indications
Treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urinary urgency and urinary frequency.
Special Populations
Prolonged half-life in geriatric patients, patients with moderate hepatic impairment (Child-Pugh class B), and patients with severe renal impairment (Clcr <30 mL/minute).
Dosage
Expected side effects of antimuscarinic agents are dry mouth, constipation, blurred vision (accommodation abnormalities), urinary retention, and dry eyes. The most common adverse events reported in patients treated with Solifenacin were dry mouth and constipation and the incidence of these side effects was higher in the 10 mg compared to the 5 mg dose group.
Side Effects
Concomitant medication with other drugs with anticholinergic properties may result in more pronounced therapeutic effects and side effects. An interval of approximately one week should be allowed after stopping treatment with Solifenacin, before commencing other anticholinergic therapy. The therapeutic effect of solifenacin may be reduced by concomitant administration of cholinergic receptor agonists. Solifenacin can reduce the effect of drugs that stimulate the motility of the gastro-intestinal tract, such as metoclopramide and cisapride.
Contraindication
Contraindications
Solifenacin should not be taken by people with a history of previous hypersensitivity to it, urinary retention, gastric retention, uncontrolled or poorly controlled closed-angle glaucoma, or severe liver disease (Child-Pugh class C). It is also contraindicated in long QT syndrome, as solifenacin, like tolterodine and darifenacin, binds to HERG channels and may prolong the QT interval. Drug Interaction
Concomitant medication with other drugs with anticholinergic properties may result in more pronounced therapeutic effects and side effects. An interval of approximately one week should be allowed after stopping treatment with Solifenacin, before commencing other anticholinergic therapy. The therapeutic effect of solifenacin may be reduced by concomitant administration of cholinergic receptor agonists. Solifenacin can reduce the effect of drugs that stimulate the motility of the gastro-intestinal tract, such as metoclopramide and cisapride.
Copyright © 2020 tasmed
.png)
